Loading...

MDGL MADRIGAL PHARMACEUTICALS INC Operational Disruptions 8-K Filing

MDRG

MDGL

MADRIGAL PHARMACEUTICALS INC

(MDGL)

2023 8-K

Show Summary

Summary

Debt Restructuring

Financial Statements

Management Change

Financial Results

Earnings Update

Financial Results

Earnings Reports

Amendment to Stock Plan

Sales Agreement with TD Sec...

Earnings Reports

Exercise of Underwriters Op...

Underwriting Agreement for ...

FDA Approval of Rezdiffra f...

Appointment of CFO

Financial Results Announcement

Financial Results Announcement

Departure of Directors or C...

Inducement Plan Adoption

Appointment of CEO and Dire...

FDA Acceptance of New Drug ...

Financial Results Announcement

Departure and Appointment o...

Amendment and Annual Meeting

Amendment to Sales Agreement

Financial Results Announcement

Financial Results Announcement

Loan Agreement Amendment

Phase 3 Clinical Trial Results

External Links:

Madrigal Pharmaceuticals announced the primary endpoint results from its Phase 3 clinical trial of resmetirom for the treatment of NASH, showing positive response rates for both doses in NASH resolution and fibrosis improvement.

AI Assistant

MADRIGAL PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.